

FertiTOX General Assembly

15/24 June 2026 (Online)



Agenda

Welcome

FertiTOX

- 1 New centres
- 2 Recruiting and follow-ups
- 3 How to deal with missing data
- 4 Suggested analyses and possible abstracts for ESHRE 2027 / papers
- 5 Time line for further data collection and data analysis in 2026
- 6 FertiTOX meeting in Frankfurt (D & A centres) September 15th
- 7 FertiTOX Swiss meeting online in autumn

PredictAYA retrospective

- 1 Transfer of FertiTOX data to the PredictAYA registry
(permission from the centres)

PredictAYA prospective

- 1 New PredictAYA registry
(information about contents, compensation for expenses, timeline)
- 2 Who is interested to contribute?

Varia

von Wolff | Germeyer | Böttcher

(max. 45 minutes)

Germeyer

Marcu | von Wolff

von Wolff | Marcu

von Wolff | Germeyer | Böttcher

von Wolff | Marcu

Germeyer | Böttcher

von Wolff

(max. 15 minutes)

von Wolff | Germeyer | Böttcher

(max. 30 minutes)

von Wolff | Germeyer | Böttcher

All

All

FertiTOX

New centres (Ethics)

Germany

Berlin-Mitte - Praxis Fertilität (KEZ)

Fachärztin Constanze Glaser

Düsseldorf - UniKid

Prof Dr Jan-Steffen Krüssel

Prof Dr Alexandra Bielfeld

Erlangen - University Hospital (Andrology)

Dr Andreas Maronna

Frankfurt - University Hospital

Dr Aynura Abbasova-Semiz

Gießen - UKGM (Andrology)

Prof Dr Hans-Christian Schuppe

Dr Jens Rosellen

Greifswald - University Hospital

Dr Paula Spring

Lübeck - UKSH Schleswig-Holstein

Prof Dr Georg Griesinger


Dr Marion Depenbusch

Magdeburg - OVGU

Fachärztin Carina Strecker

München - TUM

Prof Dr Vanadin Regina Seifert-Klauss




Follow-up

Germany

		Recruited	Total	Complete	FOLLOW-UP		Due
Centre					Incomplete	Exclusion	
1	Berlin - an der Gedächtniskirche	4	3	1	1	1	0
2	Berlin - Charité	12	2	0	0	2	2
3	Berlin-Charlottenburg - Fertility Center	54	15	15	0	0	13
4	Bonn - Venuskind am UKB	154	16	15	1	0	23
5	Dresden - Carl Gustav Carus	27	12	7	1	4	6
6	Freiburg - University Hospital	55	9	5	0	4	34
7	Hamburg - amedes experts	28	12	11	0	1	1
8	Hannover - MHH	9	5	5	0	0	2
9	Heidelberg - UKHD	244	72	45	4	23	11
10	Hildesheim - Fertility Centre	104	48	3	3	42	35
11	Karlsruhe - City Clinic	3	0	0	0	0	0
12	Kiel - UKSH	5	0	0	0	0	5
13	Leipzig - University Hospital (Andro)	86	14	14	0	0	35
14	Leipzig - University Hospital (Gyn)	2	0	0	0	0	2
15	Mannheim - UMM	5	0	0	0	0	0
16	München - LMU	12	0	0	0	0	6
17	Münster - UKM (Andro)	202	29	23	3	3	71
18	Oldenburg - Fertility Centre	1	0	0	0	0	1
19	Saarland - UKS (Homburg)	56	15	8	1	6	7
20	Tübingen - University Hospital	157	35	28	1	6	42
21	Ulm - UniFee	113	35	24	0	3	20
Total		1333	322	204	15	95	316

Recruitment

Switzerland




Follow-up

Switzerland

		FOLLOW-UP					
	Centre	Recruited	Total	Complete	Incomplete	Exclusion	Due
1	Baden - Fertility Centre	22	6	1	4	1	0
2	Basel - University Hospital	63	13	8	4	1	10
3	Bern - Inselspital (+Lindenhof)	123 (+6)	34	28	0	6	5 (+4)
4	Chur - Fontana	20	6	3	0	3	0
5	Fribourg - HFR	10	2	0	0	2	3
6	Genève- HUG	15	0	0	0	0	11
7	Lausanne - CHUV	45	7	0	5	2	10
8	Locarno - La Carità	37	2	0	0	2	10
9	Luzern - LUKS	47	9	0	1	8	9
10	Luzern - St. Anna	5	4	4	0	0	1
11	St. Gallen - YUNA	36	7	4	3	0	7
12	Winterthur - Admira	29	20	14	0	6	0
13	Zürich - 360 Grad	35	21	1	10	10	4
14	Zürich - GYN-A.R.T.	2	0	0	0	0	1
15	Zürich - Gyné invitro (Küsnacht)	5	0	0	0	0	1
16	Zürich - OVA IVF	3	1	0	1	0	0
Total		503	132	63	28	41	76

Recruitment

Austria



Follow-up

Austria

		FOLLOW-UP					
	Centre	Recruited	Total	Complete	Incomplete	Exclusion	Due
1	Graz - Med Uni	85	12	2	2	8	40
2	Innsbruck - Med Uni	106	19	10	0	9	3
Total		191	14	12	2	17	43

Follow-up



0 200 400 600 800 1000 1200

Data analysis 2026-2027

Data cleaning
Variables that are mandatory to prevent patients from being excluded

Disease	Age	Country				
Chemotherapy	Cycles (n)	Endocrine therapy	Pelvic radiation	Immunotherapy	Operation	Changes
AMH concentration before	AMH concentration after					
Sperm concentration before	Sperm concentration after					

Potential Abstracts ESHRE 2027

Primary Outcomes = Gonadotoxicity



Breast cancer

What is the impact of different chemotherapies on AMH concentration?

– in younger and older women (6? analyses/figures)

Hodgkin Lymphoma

What is the impact of different chemotherapies on AMH concentration?

– BreCADD, ABVD and BEACOPP ± ABVD (3 analyses/figures)



Testicular cancer

What is the impact of orchiectomy +/- different chemotherapies on sperm concentration?

– no chemo, 1 cycle PEB, >1 cycle PEB and other chemotherapies (3 analyses/figures)

Hodgkin-Lymphoma

What is the impact of different chemotherapies on sperm concentration

– BreCADD, ABVD and BEACOPP ± ABVD (3 analyses/figures)


Breast Cancer

AMH (pmol/L) before and approximately 1 year after completion of chemotherapy




± Therapy changes, surgery (ovaries), hormone therapy, immunotherapy and targeted therapy

EC-Tax



n=35
Chemotherapy based on anthracyclines and cyclophosphamide (epirubicin and cyclophosphamide, followed by a taxane such as paclitaxel or docetaxel)

EC-Tax + Carbo



n=18
Anthracycline-, cyclophosphamide- and platinum-based chemotherapy

Carbo-Tax



n=14
Taxane- and platinum-based chemotherapy


Hodgkin Lymphoma

AMH (pmol/L) before and approximately 1 year after completion of chemotherapy

± Surgery (ovaries), hormone therapy, immunotherapy, targeted therapy and cell therapy




BreCADD




n=8
Alkylating agents
Anthracyclines
Cyclophosphamide
Topoisomerase II inhibitors

ABVD



n=6
Alkylating agents
Antibiotic
Anthracyclines
Vinca alkaloid

BEACOPP ± ABVD




n=8
Antibiotic
Alkylating agents
Anthracyclines
Antibody-drug conjugate
Cyclophosphamide
Topoisomerase II inhibitors
Vinca alkaloid

Testicular Cancer

Sperm concentration ($10^6/\text{ml}$) before and ca. 1 year after completion of chemotherapy



No Chemotherapy




n=18
Good Prognosis (Stage I)

1 Cycle



n=14
Good prognosis (Stage I)
Antibiotic
Platinum
Topoisomerase II inhibitors

>1 Cycle




n=5
≥ Moderate prognosis (stage II-III)
Antibiotic
Platinum
Topoisomerase II inhibitors

Hodgkin Lymphoma


Sperm concentration ($10^6/\text{ml}$) before and ca. 1 year after completion of chemotherapy

BreCADD




n=7
 Alkylating agents
 Anthracyclines
 Cyclophosphamide
 Topoisomerase II inhibitors

ABVD



n=2
 Alkylating agents
 Antibiotic
 Anthracyclines
 Vinca alkaloid

BEACOPP ± A(B)VD



n=3
 Antibiotic
 Alkylating agents
 Anthracyclines
 Antibody-drug conjugate
 Cyclophosphamide
 Topoisomerase II inhibitors
 Vinca alkaloid

Potential Abstracts ESHRE 2027

Secondary Outcomes

ESHRE-Abstracts 2027-2028?

1. Prognostic factors for undergoing fertility preservation procedures

Analysis of **fertility preservation** procedures (yes/no, type) per disease

Association of **age before** cancer therapy and fertility preservation procedures (yes/no, type) per disease

Association of **children before** cancer therapy and fertility preservation procedures (yes/no, type) per disease

Association of **partnership before** cancer therapy and fertility preservation procedures (yes/no, type) per disease

Association of **BMI before** cancer therapy and fertility preservation procedures (yes/no, type) per disease

2. Fertility preservation – Safety issues

Postponement of cancer therapy due to fertility preservation per disease

Complications due to fertility preservations

3. Fertility preservation – Efficacy issues

Number of oocytes per stimulation per disease and age


Sperm concentration per disease

Turn up rate for follow up consultation per disease

Death rate per disease

BMI


before cancer treatment



Postponement


cancer therapy due to fertility preservation measures

876 No
95 Yes
66 Unknown



Postponement

of cancer therapy due to fertility preservation measures per disease, in women



Deceased patients

Female

1. Acute myeloid leukemia (C92)
2. Acute myeloid leukemia (C92)
3. Anemia – aplastic (D60–D61)
4. Breast cancer – HR-negative (Z17.1)
5. Breast cancer – HR-negative (Z17.1)
6. Breast cancer – HR-negative (Z17.1)
7. Malignant nerve sheath tumor (C47.9)
8. Osteosarcoma (C41.9)

Male

1. Rectal cancer (C20)

Timeline 2026

Data cleaning

Brainstorming what could be analysed

Main Assembly

Extended Steering Committee Meeting

Meeting D-A: Frankfurt Airport, Park Inn, Radisson Hotel

Meeting CH: online

Data analysis REDCap (D-A-CH)

Steering Committee Meeting

Statistical analysis

Abstract preparation für ESHRE

January - June

May

15/24 June

26 August (16:00 – 18:00)

15. September (11:00 – 16:00)

24 September (afternoon)

August - October

... December

November - December

January 2027

PredictAYA retrospective

PredictAYA retrospective

<http://predictaya.eu>

- Inclusion of patients with a first diagnosis by **31.12.2025** (pseudo-/anonymized).
- Which centers agree to data transfer? All centers will receive a document to sign, requesting their consent to the data transfer. This will be **discussed in detail at the meeting in September**, and approval will be obtained at that time. Written confirmation via email is mandatory.
- Data can be included in the Swedish register **from August 1st** at the earliest.
- An acknowledgment from the centers that included data is assured; PredictAYA will decide on co-authorship (the PREDICAYA consortium also believes this should happen - the final wording is still pending).



FertiTOX: German participating centres

with contact names

1. Berlin – ‘an der Gedächtniskirche’

Dr Matthias Bloechle

Dr Silk Marr

2. Berlin – Charité

Prof Dr hc Jalid Sehoul

Dr Judith Altmann

3. Berlin-Charlottenburg – Fertility Center

Prof Dr Heribert Kantenich

Dr Manja Krause

4. Berlin-Mitte – Praxis Fertilität (KEZ)

Gynaecologist Constanze Glaser

5. Bonn – Venuskind am UKB

Prof Dr Nicole Sängler

Dr Norah LA Emrich

Dr Julia John

6. Dresden – Carl Gustav Carus

PD Dr Maren Goeckenjan-Festag

7. Düsseldorf – UniKid

Prof Dr Jan-Steffen Krüssel

Prof Dr Alexandra Bielfeld

8. Erlangen – Uni (Andro)

Dr Andreas Maronna

9. Frankfurt – University Hospital

Dr Aynura Abbasova-Semiz

10. Freiburg – University Hospital

Dr Philipp Wiehle

Dr Jasmin Asberger

11. Gießen – UKGM (Andro)

Prof Dr Hans-Christian Schuppe

Dr Jens Rosellen

12. Greifswald – University Hospital

Dr Paula Spring

13. Hamburg – ‘amedes experts’

Prof Dr Frank Nawroth

14. Hannover – MHH

Prof Dr Cordula Schippert

Dr Bettina Hertel

15. Heidelberg – UKHD

Prof Dr Ariane Germeyer

16. Hildesheim – Fertility Centre

Dr Jan-Simon Lanowski

17. Karlsruhe – City Clinic

Prof Dr Andreas Müller

18. Kiel – UKSH

PD Dr Veronika Günther

PD Dr Sören von Otte

19. Leipzig – University Hospital (Andro)

Prof Dr Sonja Grunewald

20. Leipzig – University Hospital (Gyn)

Dr Julia Bartley

21. Lübeck – UKSH

Prof Dr Georg Griesinger

22. Magdeburg – OVGU

Fachärztin Carina Strecker

23. Mannheim – UMM

Dr Laura Maria Haag-Häusler

24. Marburg – UKGM (Gyn)

Dr Jennifer Muigai

25. München – LMU (Gyn)

Prof Dr Nina Rogenhofer

PD Dr Aurelia Vattai

Prof Dr Frank-Michael ‘Sascha’ Köhn (Andro)

26. München – TUM

Prof Dr Vanadin Regina Seifert-Klauss

27. Münster – UKM (Andro)

Prof Dr rer nat Verena Nordhoff

Prof Dr rer nat Stefan Schlatt

Dr Simone Bier

Dr Claudia Krallmann

28. Münster – UKM (Gyn)

Prof Dr Hermann M. Behre

Dr Tanja Sperlbaum

29. Oldenburg – Fertility Centre

Dr Jörg Hennefründ

Biologist Gabriele Remek

30. Saarland (Homburg) – UKS

Dr Simona Lucia Baus

31. Tübingen – University Hospital

Prof Dr Melanie Henes

32. Ulm – UniFee

Prof Dr Katharina Hancke

PD Dr Dr Karin Bundschu

FertiTOX: Swiss and Austrian participating centres

with contact names

SWITZERLAND

1. Baden - Fertility Centre

Dr Mischa Schneider

Dr Gabriele Rauscher

2. Basel - University Hospital

Dr Ursula Gobrecht-Keller

3. Bern - University Hospital, Inselspital

Prof Dr Michael von Wolff

4. Chur - Cantonal Hospital Graubünden, Fontana

Dr Naomi Ventura

5. Fribourg - Cantonal Hospital HFR

PD Dr Dorothea Wunder

6. Genève - University Hospital HUG

Dr Federico Del Vento

7. Lausanne - University Hospital CHUV

Dr Anna Surbone

Dr Sandrine Cuénoud

8. Locarno - Cantonal Hospital EOC, La Carità

Dr Alessandro Santi

PhD Alessandra Fusconi

SWITZERLAND

9. Luzern - Cantonal Hospital LUKS

Prof Dr Alexandra Kohl Schwartz

10. Luzern - Hirslanden, Klinik St. Anna

Dr Sabine Steimann

11. St. Gallen - YUNA

Dr Vera Hungerbühler

Dr Alice Kühn-Lichtenberg

12. Winterthur - Admira

Dr Monika Fäh

Dr Helene Saxer Gogos

13. Zürich - 360 Grad

Dr Florian Götze

14. Zürich - Gyn-A.R.T.

Gynaecologist Moritz Suerdieck

15. Zürich - Gyné invitro

Dr Michael Singer

16. Zürich - OVA IVF

Dr Peter Fehr

Dr Nikola Robert-Fasching

AUSTRIA

1. Graz - University Hospital

Dr Marisa Viola Sammer (Feurer)

2. Innsbruck - University Hospital

PD Dr Bettina Böttcher

FertiTOX: Centres that have not participated so far

GERMANY

1. Bielefeld - Fertility Centre

Dr Karl Völklein

2. Bremen - Mitte Clinic

Dr Mustafa Aydogdu

3. Erlangen - Uni (Gyn)

Prof Dr rer nat Ralf Dittrich

4. Halle - ZRA (Saale)

Prof Dr Hermann M. Behre

5. Köln - MVZ PAN-Institute

Dr Bartłomiej Berger

6. Köln - University Hospital

Prof Dr Gohar Rahimi

7. Mainz - JGU

Prof Dr Christine Skala

Dr Susanne Theis

8. München - ART Bogenhausen

Dr Stephanie Ziehr

9. Regensburg - Profertilita

Dr Karla Gisch-Pratsch

Dr Christine Reißmann

10. Rostock - Fertility Centre

Dr Anne Koenen

PD Dr Heiner Müller

11. Würzburg - University Hospital

Dr Michael Schwab

SWITZERLAND

1. Basel - Fertility Centre (Viollier)

Dr Erika Ocon

2. Cham Fertility Centre

Dr Markus Bleichenbacher

3. Lausanne - CPMA

Dr Nicolas Vulliemoz

4. Olten - fertisuisse

Dr Astrid Ahler

5. Zürich - USZ

PD Dr Ruth Stiller

Dr Angela Niggli

AUSTRIA

1. Linz - JKU

PD Dr Omar Josef Shebl

2. Salzburg - PMU

Dr Katharina Winkler-Crepaz

3. Wien - MedUni & St. Anna Kinderspitals

PD Dr Julian Marschalek

PD DDr Marlene Hager

PredictAYA prospective

PredictAYA prospective

<http://predictaya.eu>

- Inclusion of patients with a first diagnosis from **01.01.2025** onwards
- Follow-Up: **1 + 3 + 5 years after diagnosis**
- Inquiry regarding participation in the **genetics study** at the 1st follow-up or subsequent follow-up

Prerequisite

- breast cancer or Hodgkin lymphoma
- patient age at enrolment max. 35 years
- AMH min. 1.0 ng/ml (1.0 microgram/L or 7.14 pmol/L)



Varia

Meeting (D-A)

Frankfurt

Park Inn, Radisson Hotel

Frankfurt Airport

15 September 2026

11:00 – 16:00



Meeting (CH)

Online

Thursday afternoon, 24 September



Sponsors



krebsliga schweiz

Swiss cancer league



Deutsche Krebshilfe
HELFEN. FORSCHEN. INFORMIEREN.

Deutsche Krebshilfe



Caring Innovation

IBSA Institut Biochimique SA



Theramex
For Women, For Health

Theramex Switzerland GmbH

FERRING

PHARMACEUTICALS

Ferring Pharmaceuticals SA